BioSpace News Archive

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial results and provided a business update.

PinCell announced that two pre-clinical studies carried out in Japan by a specialized team indicate that its lead candidate, PC111, can be effective in treating Stevens-Johnson Syndrome, an acute skin disease with no approved therapy.

Novarad’s VisAR, a surgical navigation system that uses augmented reality, has received clearance from Indonesia’s FDA for intraoperative use in stereotactic spinal surgery.

Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Innate Pharma SA announced the voting results of its shareholders at the Annual General Meeting, which took place on May 12, 2023, in Marseille.

Zomedica Corp. announced that Larry Heaton, Chief Executive Officer, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023.

AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the “Company” or “Aires”) announces that it has closed a non-brokered private placement of units (the “Units”) through the issuance of 7,844,000 Units at a price of $0.05 per Unit for aggregate gross proceeds of $392,200 (the “Offering”).